

Media Release

Zug, 16 October 2023

Ad hoc announcement pursuant to Art. 53 LR

HBM Healthcare Investments activates share buyback programme

The discount of the share price to the reported net asset value per share (NAV) has widened in recent days to an extent that the Board of Directors and the Management of HBM Healthcare Investments are convinced does not reflect the fundamental development and future prospects of the Company. For this reason, HBM Healthcare Investments has brought forward the publication of the Half-Year Report as at 30 September 2023 by a few days to today. The half-year results and NAV per share of CHF 237.22 as at 30 September 2023, which were already published at the beginning of October, were confirmed.

The Board of Directors and the Management are of the opinion that the carefully assembled portfolio is of high quality and its value potential is currently not adequately reflected in the Company's market capitalisation. The Company will therefore use a portion of the available cash to implement the current share buyback programme.

The share buybacks will be carried out via the second trading line on the SIX Swiss Exchange in compliance with regulatory volume restrictions and within the possibilities of freely available liquidity. Careful management of the available funds will continue to be a high priority in order to secure the financing of the existing portfolio companies and to take advantage of investment opportunities as they arise.

Further information on the share buyback programme can be found on our website at <https://www.hbmhealthcare.com/en/investors/information>.

Contact

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative

to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to U.S. persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments Ltd's securities were not issued in accordance with the U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.